Rose C, Kamby C, Mouridsen H T, Bastholt L, Brincker H, Skovgaard-Poulsen H, Andersen A P, Loft H, Dombernowsky P, Andersen K W
Breast Cancer Res Treat. 1986;7 Suppl:S45-50.
The therapeutic efficacy of combined endocrine therapy with tamoxifen, aminoglutethimide and hydrocortisone (T+AG+H) was evaluated against treatment with tamoxifen (T) alone in 210 patients above 65 years of age with metastatic breast cancer. The treatment results have been assessed for the 166 fully evaluable patients and were the following for the T and T+AG+H groups, respectively: PD: 31 and 35%; NC: 35 and 37%; PR: 13 and 16%; and CR: 21 and 12%. The overall treatment results are not statistically different (p = 0.35) and the 95% C.L. of the difference of the response rates are -8% to +20%. The median duration of remission was approximately 24 months in both treatment groups (p = 0.31). The time to treatment failure was comparable with median values of 10 and 8 months in the T and the T+AG+H groups respectively (p = 0.17). Toxicity was more frequent and severe in the combined treatment group and could in most instances be attributed to treatment with AG+H. In conclusion, the simultaneous use of T and AG and H does not seem to improve the therapeutic results in postmenopausal patients with advanced breast cancer.
对210例65岁以上的转移性乳腺癌患者，评估了他莫昔芬、氨鲁米特和氢化可的松联合内分泌治疗（T+AG+H）与单纯他莫昔芬（T）治疗的疗效。已对166例可全面评估的患者的治疗结果进行了评估，T组和T+AG+H组的结果分别如下：疾病进展（PD）：31%和35%；病情稳定（NC）：35%和37%；部分缓解（PR）：13%和16%；完全缓解（CR）：21%和12%。总体治疗结果无统计学差异（p = 0.35），缓解率差异的95%置信区间为-8%至+20%。两个治疗组的中位缓解期均约为24个月（p = 0.31）。治疗失败时间相当，T组和T+AG+H组的中位值分别为10个月和8个月（p = 0.17）。联合治疗组的毒性更频繁且更严重，在大多数情况下可归因于AG+H治疗。总之，同时使用T、AG和H似乎并不能改善绝经后晚期乳腺癌患者的治疗效果。
